Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate if the Medication Gabapentin Lessens Vulvar Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All women, ages 18 years and older with the diagnosis of vulvodynia or VVS (by Friedrich's criteria), who present to the University of Iowa Vulvar Vaginal Disease Clinic.~Exclusion Criteria:~* Vulvar Vaginal Disease clinic patients who are pregnant, less than 3 months postpartum, breast-feeding, non-English speaking, or have contraindication to use of gabapentin due to allergy or renal disease (serum creatinine level greater than 1.4).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Gabapentin (Type: ACTIVE_COMPARATOR): Gabapentin (Neurontin) titration and dosing for total of 8 weeks (Cross over)
- Placebo oral capsule (Type: PLACEBO_COMPARATOR): Placebo titration and dosing for total of 8 weeks (Cross over)

Based on this trial design, predict the completion outcome and termination type (if applicable).